A survey of U.S. adults from 2023 found that 77 percent strongly favored requiring Medicare to cover the costs of FDA approved drugs and therapies that can slow the progression of Alzheimer's disease. This statistic displays the share of U.S. adults who favor requiring Medicare to cover the costs of FDA approved drugs and therapies that can slow the progression of Alzheimer's disease.
Share of U.S. adults who favor requiring Medicare to cover the costs of FDA approved drugs and therapies that can slow the progression of Alzheimer's disease as of 2023
Original question: "Do you favor or oppose requiring Medicare to cover the costs of FDA approved
drugs and therapies that can slow the progression of Alzheimer's
disease?"
Missing percentage points to 100 percent are probably due to rounding.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Lake Research Partners, & Public Opinion Strategies. (May 22, 2023). Share of U.S. adults who favor requiring Medicare to cover the costs of FDA approved drugs and therapies that can slow the progression of Alzheimer's disease as of 2023 [Graph]. In Statista. Retrieved November 13, 2024, from https://www-statista-com.ezproxy.canberra.edu.au/statistics/1440197/adults-who-favor-medicare-covering-the-cost-of-alzheimers-drugs/
Lake Research Partners, und Public Opinion Strategies. "Share of U.S. adults who favor requiring Medicare to cover the costs of FDA approved drugs and therapies that can slow the progression of Alzheimer's disease as of 2023." Chart. May 22, 2023. Statista. Accessed November 13, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/1440197/adults-who-favor-medicare-covering-the-cost-of-alzheimers-drugs/
Lake Research Partners, Public Opinion Strategies. (2023). Share of U.S. adults who favor requiring Medicare to cover the costs of FDA approved drugs and therapies that can slow the progression of Alzheimer's disease as of 2023. Statista. Statista Inc.. Accessed: November 13, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/1440197/adults-who-favor-medicare-covering-the-cost-of-alzheimers-drugs/
Lake Research Partners, and Public Opinion Strategies. "Share of U.S. Adults Who Favor Requiring Medicare to Cover The Costs of Fda Approved Drugs and Therapies That Can Slow The Progression of Alzheimer's Disease as of 2023." Statista, Statista Inc., 22 May 2023, https://www-statista-com.ezproxy.canberra.edu.au/statistics/1440197/adults-who-favor-medicare-covering-the-cost-of-alzheimers-drugs/
Lake Research Partners & Public Opinion Strategies, Share of U.S. adults who favor requiring Medicare to cover the costs of FDA approved drugs and therapies that can slow the progression of Alzheimer's disease as of 2023 Statista, https://www-statista-com.ezproxy.canberra.edu.au/statistics/1440197/adults-who-favor-medicare-covering-the-cost-of-alzheimers-drugs/ (last visited November 13, 2024)
Share of U.S. adults who favor requiring Medicare to cover the costs of FDA approved drugs and therapies that can slow the progression of Alzheimer's disease as of 2023 [Graph], Lake Research Partners, & Public Opinion Strategies, May 22, 2023. [Online]. Available: https://www-statista-com.ezproxy.canberra.edu.au/statistics/1440197/adults-who-favor-medicare-covering-the-cost-of-alzheimers-drugs/
